Core Viewpoint - Ribocure Pharmaceuticals AB, a subsidiary of Ribocure Bio-B (06938), has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals, Inc. to develop innovative siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) using Ribocure's RiboGalSTAR™ platform [1] Group 1 - Ribocure Bio-B's stock rose over 13%, specifically by 13.65%, reaching HKD 79.95 with a trading volume of HKD 6.4582 million [1] - The agreement allows Madrigal Pharmaceuticals exclusive rights for the global research, production, and commercialization of multiple clinical-stage siRNA assets in the MASH field [1] - Ribocure Bio-B will receive an upfront payment of USD 60 million and is eligible for up to USD 4.4 billion in total payments, including milestone payments related to clinical development, regulatory approval, and commercial sales [1]
港股异动 | 瑞博生物-B(06938)涨超13% 与Madrigal达成44亿美元全球独家许可协议